GlassScriptPhysician profile
Ashley M Warmoth
NPI 1801154794
$2,868.35
in general payments reported to CMS, 2019-2025
19 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $195 · 2021: $257 · 2022: $190 · 2023: $415 · 2024: $296 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $362.82 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $356.76 | 2019-2025 | |
| Novo Nordisk INC | $330.81 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $326.67 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $323.66 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $323.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $218.81 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $203.87 | 2019-2025 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.21 | 2019-2021 | |
| Axonics, INC. | $63.95 | 2023 | Axonics |
| Esperion Therapeutics, INC. | $49.07 | 2024-2025 | Nexletol |
| Boston Scientific Corporation | $42.69 | 2019-2023 | Watchman Flx |
| Allergan, INC. | $39.29 | 2020 | |
| Amarin Pharma, INC. | $28.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.58 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $20.33 | 2023 | Tymlos |
| Ironshore Pharmaceuticals INC. | $20.18 | 2019 | |
| Medtronic, INC. | $15.72 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Warmoth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.